CURE’s kidney cancer page is an extensive resource of cancer information featuring the latest kidney cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on kidney cancer.
September 27th 2017
Sumanta Kumar Pal, M.D., associate professor, Department of Medical Oncology, City of Hope, covered the scope of exciting genitourinary cancer data presented at the 2017 ESMO Congress, with a sharp focus on the CABOSUN and CheckMate-214 trials.
September 15th 2017
The latest drugs for advanced kidney cancer are stirring optimism.
September 14th 2017
The Food and Drug Administration approved the first ever biosimilar to treat a variety of cancers.
August 22nd 2017
In an interview with CURE, Badani, a professor of Urology at Mount Sinai Hospital, discusses the benefits of robotic surgery in RCC.
June 21st 2017
Cabometyx had better progression-free survival rates than Sutent (sunitinib) for certain patients with renal cell carcinoma.
June 14th 2017
Progression-free survival (PFS) was not significantly improved with the combination of dalantercept plus Inlyta (axitinib) in patients with advanced renal cell carcinoma (RCC) compared with placebo, according to the results from the phase 2 DART trial.
June 7th 2017
Bavencio and Inlyta together produced a promising response for some patients with renal cell carcinoma.
May 5th 2017
There are 16 known genes that cause kidney cancer and at least 13 different types of inherited kidney cancer, emphasizing the need to understand genetic differences between these disease.
March 15th 2017
James Brugarolas, M.D., Ph.D., discusses the importance of spotting the difference between a metastatic kidney cancer lesion and a separate lung cancer. The difference can save patients' lives.
February 24th 2017
David McDermott, M.D. discusses new advances made to treat kidney cancer.
February 23rd 2017
An independent data monitoring committee recommended that the phase 3 ADAPT trial exploring rocapuldencel-T (AGS-003) for the frontline treatment of metastatic renal cell carcinoma (mRCC) be stopped, but Argos Therapeutics explained that they will keep the trial open.
February 22nd 2017
A randomized trial showed that the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) has some promise for the frontline treatment of some patients with RCC.
February 14th 2017
A recent study found that patients with metastatic renal cell carcinoma may see extended response even after stopping immunotherapy treatment.
February 14th 2017
Patients with metastatic kidney cancer may see a decreased efficacy of their immunotherapy regimen if they recently took antibiotics.
February 9th 2017
Sutent treatment breaks seem to have no effect on clinical efficacy for patients with renal cell carcinoma.
January 28th 2017
CURE spoke with Neeraj Agarwal, M.D., about the underreporting and underemphasizing of toxicities with PD-1 inhibitors in renal cell carcinoma.
January 28th 2017
Vaccines are currently being tested in their potential to improve immunotherapy responses for patients with renal cell carcinoma.
January 26th 2017
Elizabeth Plimack, M.D., discusses an update on the CheckMate-025 trial, comparing Opdivo to Afinitor in patients with metastatic renal cell carcinoma.
January 21st 2017
David F. McDermott, M.D., is optimistic about combination regimens shaping the treatment landscape for renal cell carcinoma.
January 12th 2017
After the approvals of agents in the second-line setting, researchers are now turning to improving the frontline treatment of kidney cancer.
December 19th 2016
Will the newly approved kidney cancer treatments eventually end up in the frontline setting? Expert Chung-Han (Joe) Lee, M.D., weighs in.
December 14th 2016
Obesity can negatively affect cancer treatment outcomes, trigger disease recurrence and shorten longevity. Organized weight loss programs and exercise can help patients protect themselves.
December 5th 2016
Immunotherapy combinations are on the horizon for the treatment of renal cell carcinoma, Robert J. Motzer, M.D., says.
December 3rd 2016
Melanoma should not be considered to be in a "special category" that responds well to immunotherapy, according to Christian M. Capitini, M.D., assistant professor of Pediatrics at the University of Wisconsin.
November 30th 2016
A panel of experts recently discussed the evolving field of immunotherapy for solid tumor types.